Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables

American Journal of Geriatric Psychiatry

Volumn 25, Issue 1, 2017, Pages 50-61

  Lee, Ellen E ^a,b   Hong, Suzi ^a   Martin, Averria Sirkin ^a,b   Eyler, Lisa T ^a,c   Jeste, Dilip V ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California San Diego School of Medicine   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

cytokines; IFN ; IL 6; inflammation; schizophrenia; TNF

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CLINICAL FEATURE; COMORBIDITY ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTPATIENT; PHYSICAL WELL-BEING; POSITIVE SYNDROME; PROTEIN BLOOD LEVEL; PSYCHOLOGICAL WELL-BEING; SCHIZOPHRENIA; BLOOD; COMORBIDITY; HEALTH STATUS; PSYCHOLOGY; SATISFACTION;

ADULT; CASE-CONTROL STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; CYTOKINES; DEPRESSION; FEMALE; HEALTH STATUS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PERSONAL SATISFACTION; SCHIZOPHRENIA;

EID: 85004024109     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2016.09.009     Document Type: Article

References (118)

1. 1 World Health Organization, The World Health Report 2001: Mental Health: New Understanding, New Hope. 2001, World Health Organization, Geneva, Switzerland.
2. 2 Whiteford, H.A., Degenhardt, L., Rehm, J., et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382 (2013), 1575–1586.
3. 3 Hennekens, C.H., Hennekens, A.R., Hollar, D., et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150 (2005), 1115–1121.
4. 4 Saha, S., Chant, D., McGrath, J., A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry 64 (2007), 1123–1131.
5. 5 Meyer, J.M., Nasrallah, H.A., Medical Illness and Schizophrenia. 2nd ed., 2009, American Psychiatric Publishing, Arlington, VA.
6. 6 Jeste, D.V., Wolkowitz, O.M., Palmer, B.W., Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia. Schizophr Bull 37 (2011), 451–455.
7. 7 Nasrallah, H.A., Harvey, P.D., Casey, D., et al. The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: a focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization. Schizophr Res 166 (2015), 69–79.
8. 8 Kirkpatrick, B., Messias, E., Harvey, P.D., et al. Is schizophrenia a syndrome of accelerated aging?. Schizophr Bull 34 (2008), 1024–1032.
9. 9 Ohayon, M.M., Schatzberg, A.F., Biomarkers and classifications. J Psychiatr Res 41 (2007), 623–624.
10. 10 Dickerson, F., Stallings, C., Origoni, A., et al. Inflammatory markers in recent onset psychosis and chronic schizophrenia. Schizophr Bull 42 (2016), 134–141.
11. 11 Joseph, J., Depp, C., Martin, A.S., et al. Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups. Schizophr Res 168 (2015), 456–460.
12. 12 Miller, B.J., Culpepper, N., Rapaport, M.H., C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin Schizophr Relat Psychoses 7 (2014), 223–230.
13. 13 Maes, M., Bosmans, E., Calabrese, J., et al. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 29 (1995), 141–152.
14. 14 Naudin, J., Mege, J., Azorin, J., et al. Elevated circulating levels of IL-6 in schizophrenia. Schizophr Res 20 (1996), 269–273.
15. 15 Lin, A., Kenis, G., Bignotti, S., et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 32 (1998), 9–15.
16. 16 Mondelli, V., Ciufolini, S., Belvederi Murri, M., et al. Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophr Bull 41 (2015), 1162–1170.
17. 17 Kirkpatrick, B., Miller, B.J., Inflammation and schizophrenia. Schizophr Bull 39 (2013), 1174–1179.
18. 18 Iosif, R.E., Ekdahl, C.T., Ahlenius, H., et al. Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci 26 (2006), 9703–9712.
19. 19 O'Brien, S.M., Scully, P., Dinan, T.G., Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Res 160 (2008), 256–262.
20. 20 Brinholi, F.F., Noto, C., Maes, M., et al. Lowered paraoxonase 1 (PON1) activity is associated with increased cytokine levels in drug naive first episode psychosis. Schizophr Res 166 (2015), 225–230.
21. 21 Song, X., Fan, X., Song, X., et al. Elevated levels of adiponectin and other cytokines in drug naive, first episode schizophrenia patients with normal weight. Schizophr Res 150 (2013), 269–273.
22. 22 Pollmacher, T., Hinze-Selch, D., Mullington, J., Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 16 (1996), 403–409.
23. 23 Na, K.S., Kim, Y.K., Monocytic, Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology 56 (2007), 55–63.
24. 24 Theodoropoulou, S., Spanakos, G., Baxevanis, C.N., et al. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr Res 47 (2001), 13–25.
25. 25 Monteleone, P., Fabrazzo, M., Tortorella, A., et al. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res 71 (1997), 11–17.
26. 26 Kowalski, J., Blada, P., Kucia, K., et al. Neuroleptics normalize increased release of interleukin-1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia. Schizophr Res 50 (2001), 169–175.
27. 27 Garcia-Miss Mdel, R., Perez-Mutul, J., Lopez-Canul, B., et al. Folate, homocysteine, interleukin–6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia. J Psychiatr Res 44 (2010), 441–446.
28. 28 Kim, Y.K., Myint, A.M., Verkerk, R., et al. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 59 (2009), 123–129.
29. 29 Erbagci, A.B., Herken, H., Koyluoglu, O., et al. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm 10 (2001), 109–115.
30. 30 Haack, M., Hinze-Selch, D., Fenzel, T., et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 33 (1999), 407–418.
31. 31 Xu, H.M., Wei, J., Hemmings, G.P., Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia. Br J Psychiatry 164 (1994), 251–253.
32. 32 Coelho, F.M., Reis, H.J., Nicolato, R., et al. Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia. Neuroimmunomodulation 15 (2008), 140–144.
33. 33 Baker, I., Masserano, J., Wyatt, R.J., Serum cytokine concentrations in patients with schizophrenia. Schizophr Res 20 (1996), 199–203.
34. 34 Kunz, M., Cereser, K.M., Goi, P.D., et al. Serum levels of IL-6, IL-10 and TNF-alpha in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev Bras Psiquiatr 33 (2011), 268–274.
35. 35 Pedrini, M., Massuda, R., Fries, G.R., et al. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res 46 (2012), 819–824.
36. 36 Kaminska, T., Wysocka, A., Marmurowska-Michalowska, H., et al. Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch Immunol Ther Exp (Warsz) 49 (2001), 439–445.
37. 37 Xiong, P., Zeng, Y., Wu, Q., et al. Combining serum protein concentrations to diagnose schizophrenia: a preliminary exploration. J Clin Psychiatry 75 (2014), 794–801.
38. 38 Schmitt, A., Bertsch, T., Tost, H., et al. Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. Neuropsychiatr Dis Treat 1 (2005), 171–177.
39. 39 Schattner, A., Cori, Y., Hahn, T., et al. No evidence for autoimmunity in schizophrenia. J Autoimmun 9 (1996), 661–666.
40. 40 Tian, L., Tan, Y., Chen, D., et al. Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 54 (2014), 259–264.
41. 41 Francesconi, L.P., Cereser, K.M., Mascarenhas, R., et al. Increased annexin-V and decreased TNF-alpha serum levels in chronic-medicated patients with schizophrenia. Neurosci Lett 502 (2011), 143–146.
42. 42 Lv, M.H., Tan, Y.L., Yan, S.X., et al. Decreased serum TNF-alpha levels in chronic schizophrenia patients on long-term antipsychotics: correlation with psychopathology and cognition. Psychopharmacology (Berl) 232 (2015), 165–172.
43. 43 Al-Asmari, A.K., Khan, M.W., Inflammation and schizophrenia: alterations in cytokine levels and perturbation in antioxidative defense systems. Hum Exp Toxicol 33 (2014), 115–122.
44. 44 Dunjic-Kostic, B., Jasovic-Gasic, M., Ivkovic, M., et al. Serum levels of interleukin–6 and tumor necrosis factor-alpha in exacerbation and remission phase of schizophrenia. Psychiatr Danub 25 (2013), 55–61.
45. 45 Petersen, A.M., Pedersen, B.K., The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 57:suppl 10 (2006), 43–51.
46. 46 Akiyama, K., Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr Res 37 (1999), 97–106.
47. 47 Al-Hakeim, H.K., Al-Rammahi, D.A., Al-Dujaili, A.H., IL-6, IL-18, sIL-2R, and TNFalpha proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation. J Affect Disord 182 (2015), 106–114.
48. 48 Lin, C.C., Chang, C.M., Chang, P.Y., et al. Increased interleukin-6 level in Taiwanese schizophrenic patients. Chang Gung Med J 34 (2011), 375–381.
49. 49 Kubistova, A., Horacek, J., Novak, T., Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls. Psychiatr Danub 24:suppl 1 (2012), S153–S156.
50. 50 An, H.M., Tan, Y.L., Shi, J., et al. Altered IL-2, IL-6 and IL-8 serum levels in schizophrenia patients with tardive dyskinesia. Schizophr Res 162 (2015), 261–268.
51. 51 Beumer, W., Drexhage, R.C., De Wit, H., et al. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 37 (2012), 1901–1911.
52. 52 Chang, S.H., Chiang, S.Y., Chiu, C.C., et al. Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia. Psychiatry Res 187 (2011), 341–346.
53. 53 Frydecka, D., Misiak, B., Pawlak-Adamska, E., et al. Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation. Eur Arch Psychiatry Clin Neurosci 265 (2015), 449–459.
54. 54 Schwieler, L., Larsson, M.K., Skogh, E., et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia—significance for activation of the kynurenine pathway. J Psychiatry Neurosci 40 (2015), 126–133.
55. 55 Kalmady, S.V., Venkatasubramanian, G., Shivakumar, V., et al. Relationship between interleukin-6 gene polymorphism and hippocampal volume in antipsychotic-naive schizophrenia: evidence for differential susceptibility?. PLoS ONE, 9, 2014, e96021.
56. 56 Sasayama, D., Hattori, K., Wakabayashi, C., et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res 47 (2013), 401–406.
57. 57 Zakharyan, R., Petrek, M., Arakelyan, A., et al. Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. Tissue Antigens 80 (2012), 136–142.
58. 58 Fernandez-Egea, E., Bernardo, M., Donner, T., et al. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry 194 (2009), 434–438.
59. 59 Frommberger, U.H., Bauer, J., Haselbauer, P., et al. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 247 (1997), 228–233.
60. 60 Ganguli, R., Yang, Z., Shurin, G., et al. Serum interleukin–6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 51 (1994), 1–10.
61. 61 Neelamekam, S., Nurjono, M., Lee, J., Regulation of interleukin-6 and leptin in schizophrenia patients: a preliminary analysis. Clin Psychopharmacol Neurosci 12 (2014), 209–214.
62. 62 Barak, V., Barak, Y., Levine, J., et al. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. J Basic Clin Physiol Pharmacol 6 (1995), 61–69.
63. 63 Prasad, K.M., Upton, C.H., Nimgaonkar, V.L., et al. Differential susceptibility of white matter tracts to inflammatory mediators in schizophrenia: an integrated DTI study. Schizophr Res 161 (2015), 119–125.
64. 64 Shintani, F., Kanba, S., Maruo, N., et al. Serum interleukin-6 in schizophrenic patients. Life Sci 49 (1991), 661–664.
65. 65 Kim, Y.K., Kim, L., Lee, M.S., Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 44 (2000), 165–175.
66. 66 Hornberg, M., Arolt, V., Wilke, I., et al. Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia. Schizophr Res 15 (1995), 237–242.
67. 67 Borovcanin, M., Jovanovic, I., Radosavljevic, G., et al. Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response. Schizophr Res 147 (2013), 103–109.
68. 68 Arolt, V., Weitzsch, C., Wilke, I., et al. Production of interferon-gamma in families with multiple occurrence of schizophrenia. Psychiatry Res 66 (1997), 145–152.
69. 69 Arolt, V., Rothermundt, M., Wandinger, K.P., et al. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 5 (2000), 150–158.
70. 70 Wilke, I., Arolt, V., Rothermundt, M., et al. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 246 (1996), 279–284.
71. 71 Krause, D., Weidinger, E., Dippel, C., et al. Impact of different antipsychotics on cytokines and tryptophan metabolites in stimulated cultures from patients with schizophrenia. Psychiatr Danub 25 (2013), 389–397.
72. 72 Inglot, A.D., Leszek, J., Piasecki, E., et al. Interferon responses in schizophrenia and major depressive disorders. Biol Psychiatry 35 (1994), 464–473.
73. 73 Rothermundt, M., Arolt, V., Weitzsch, C., et al. Production of cytokines in acute schizophrenic psychosis. Biol Psychiatry 40 (1996), 1294–1297.
74. 74 Moises, H.W., Schindler, L., Leroux, M., et al. Decreased production of interferon alpha and interferon gamma in leucocyte cultures of schizophrenic patients. Acta Psychiatr Scand 72 (1985), 45–50.
75. 75 Preble, O.T., Torrey, E.F., Serum interferon in patients with psychosis. Am J Psychiatry 142 (1985), 1184–1186.
76. 76 Avgustin, B., Wraber, B., Tavcar, R., Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. Croat Med J 46 (2005), 268–274.
77. 77 Gattaz, W.F., Dalgalarrondo, P., Schroder, H.C., Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected. Schizophr Res 6 (1992), 237–241.
78. 78 Katila, H., Cantell, K., Hirvonen, S., et al. Production of interferon-alpha and gamma by leukocytes from patients with schizophrenia. Schizophr Res 2 (1989), 361–365.
79. 79 Becker, D., Kritschmann, E., Floru, S., et al. Serum interferon in first psychotic attack. Br J Psychiatry 157 (1990), 136–138.
80. 80 Chiang, S.S., Riedel, M., Schwarz, M., et al. Is T-helper type 2 shift schizophrenia-specific? Primary results from a comparison of related psychiatric disorders and healthy controls. Psychiatry Clin Neurosci 67 (2013), 228–236.
81. 81 Rawji, K.S., Mishra, M.K., Michaels, N.J., et al. Immunosenescence of microglia and macrophages: impact on the ageing central nervous system. Brain 139 (2016), 653–661.
82. 82 Wei, J., Xu, H., Davies, J.L., et al. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci 51 (1992), 1953–1956.
83. 83 Morimoto, Y., Conroy, S.M., Ollberding, N.J., et al. Ethnic differences in serum adipokine and C-reactive protein levels: the multiethnic cohort. Int J Obes (Lond) 38 (2014), 1416–1422.
84. 84 O'Connell, K.E., Thakore, J., Dev, K.K., Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine. Schizophr Res 156 (2014), 1–8.
85. 85 Weiner, S.D., Ahmed, H.N., Jin, Z., et al. Systemic inflammation and brachial artery endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA). Heart 100 (2014), 862–866.
86. 86 First, M., Spitzer, R.L., Gibbon, M., et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). 2002, Biometrics Research, New York State Psychiatric Institute, New York, NY.
87. 87 Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59:suppl 20 (1998), 22–33 quiz 34-57.
88. 88 van den Berg, E., Ruis, C., Biessels, G.J., et al. The Telephone Interview for Cognitive Status (Modified): relation with a comprehensive neuropsychological assessment. J Clin Exp Neuropsychol 34 (2012), 598–605.
89. 89 Ware, J.E. Jr, Sherbourne, C.D., The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992), 473–483.
90. 90 Andreasen, N.C., Olsen, S., Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry 39 (1982), 789–794.
91. 91 Kroenke, K., Spitzer, R.L., Williams, J.B., The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16 (2001), 606–613.
92. 92 Linn, B.S., Linn, M.W., Gurel, L., Cumulative illness rating scale. J Am Geriatr Soc 16 (1968), 622–626.
93. 93 Andreasen, N.C., Arndt, S., Alliger, R., et al. Symptoms of schizophrenia. Methods, meanings, and mechanisms. Arch Gen Psychiatry 52 (1995), 341–351.
94. 94 Fucetola, R., Seidman, L.J., Kremen, W.S., et al. Age and neuropsychologic function in schizophrenia: a decline in executive abilities beyond that observed in healthy volunteers. Biol Psychiatry 48 (2000), 137–146.
95. 95 Wobrock, T., Ecker, U.K., Scherk, H., et al. Cognitive impairment of executive function as a core symptom of schizophrenia. World J Biol Psychiatry, 2008, 1–10.
96. 96 Delis, D., Kaplan, E., Kramer, J., Delis-Kaplan Executive Function Scale (D-KEFS): Examiner's Manual. 2001, The Psychological Corporation, San Antonio, TX.
97. 97 Yeh, E.T., Willerson, J.T., Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 107 (2003), 370–371.
98. 98 Slavich, G.M., Irwin, M.R., From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull 140 (2014), 774–815.
99. 99 Eyre, H.A., Air, T., Pradhan, A., et al. A meta-analysis of chemokines in major depression. Prog Neuropsychopharmacol Biol Psychiatry 68 (2016), 1–8.
100. 100 Eker, S.S., Yavasci, E.O., Cangur, S., et al. Can BDNF and IL-2 be indicators for the diagnosis in schizophrenic patients with depressive symptoms?. Acta Neuropsychiatr 26 (2014), 291–297.
101. 101 Noto, C., Ota, V.K., Santoro, M.L., et al. Effects of depression on the cytokine profile in drug naive first-episode psychosis. Schizophr Res 164 (2015), 53–58.
102. 102 Smagula, S.F., Lotrich, F.E., Aizenstein, H.J., et al. Immunological biomarkers associated with brain structure and executive function in late-life depression: exploratory pilot study. Int J Geriatr Psychiatry, 2016, 10.1002/gps.4512.
103. 103 Raison, C.L., Miller, A.H., Role of inflammation in depression: implications for phenomenology, pathophysiology and treatment. Mod Trends Pharmacopsychiatri 28 (2013), 33–48.
104. 104 Strawbridge, R., Arnone, D., Danese, A., et al. Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol 25 (2015), 1532–1543.
105. 105 Michaud, M., Balardy, L., Moulis, G., et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc 14 (2013), 877–882.
106. 106 Baumeister, D., Russell, A., Pariante, C.M., et al. Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factors. Soc Psychiatry Psychiatr Epidemiol 49 (2014), 841–849.
107. 107 Bermudez, E.A., Rifai, N., Buring, J.E., et al. Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol 89 (2002), 1117–1119.
108. 108 Helmersson, J., Larsson, A., Vessby, B., et al. Active smoking and a history of smoking are associated with enhanced prostaglandin F(2alpha), interleukin-6 and F2-isoprostane formation in elderly men. Atherosclerosis 181 (2005), 201–207.
109. 109 Bostrom, L., Linder, L.E., Bergstrom, J., Clinical expression of TNF-alpha in smoking-associated periodontal disease. J Clin Periodontol 25 (1998), 767–773.
110. 110 Bostrom, L., Linder, L.E., Bergstrom, J., Smoking and crevicular fluid levels of IL-6 and TNF-alpha in periodontal disease. J Clin Periodontol 26 (1999), 352–357.
111. 111 Cesar-Neto, J.B., Duarte, P.M., de Oliveira, M.C., et al. Smoking modulates interferon-gamma expression in the gingival tissue of patients with chronic periodontitis. Eur J Oral Sci 114 (2006), 403–408.
112. 112 Ouyang, Y., Virasch, N., Hao, P., et al. Suppression of human IL-1beta, IL-2, IFN-gamma, and TNF-alpha production by cigarette smoke extracts. J Allergy Clin Immunol 106 (2000), 280–287.
113. 113 Soliman, D.M., Twigg, H.L. 3rd, Cigarette smoking decreases bioactive interleukin-6 secretion by alveolar macrophages. Am J Physiol 263 (1992), L471–L478.
114. 114 Mian, M.F., Lauzon, N.M., Stampfli, M.R., et al. Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke. J Leukoc Biol 83 (2008), 774–784.
115. 115 Gaschler, G.J., Zavitz, C.C., Bauer, C.M., et al. Cigarette smoke exposure attenuates cytokine production by mouse alveolar macrophages. Am J Respir Cell Mol Biol 38 (2008), 218–226.
116. 116 Kraemer, H.C., Messages for clinicians: moderators and mediators of treatment outcome in randomized clinical trials. Am J Psychiatry 173 (2016), 672–679.
117. 117 Kraemer, H.C., Toward non-parametric and clinically meaningful moderators and mediators. Stat Med 27 (2008), 1679–1692.
118. 118 Muller, N., Myint, A.M., Krause, D., et al. Anti-inflammatory treatment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 42 (2013), 146–153.